Anti-platelets in diabetes management

Area of Science:

• Cardiology
• Diabetology
• Pharmacology

Background:

• Diabetes mellitus is a significant risk factor for cardiovascular disease (CVD).
• Anti-platelet therapy is crucial for preventing thrombotic events in patients with or at high risk for CVD.
• Optimizing anti-platelet use in diabetic populations is essential for cardiovascular risk reduction.

Purpose of the Study:

• To determine the prevalence of anti-platelet therapy use in diabetic patients.
• To assess the role of contraindications in limiting anti-platelet therapy prescription in this cohort.
• To evaluate anti-platelet prescribing patterns in relation to cardiovascular disease history and risk factors.

Main Methods:

• Retrospective analysis of 726 diabetic patients attending a private clinic.
• Data collection on anti-platelet medication use, history of cardiovascular disease (CVD), and presence of CVD risk factors.
• Assessment of contraindications to anti-platelet therapy.

Main Results:

• 87.1% of diabetic patients with a history of CVD were on anti-platelet therapy.
• Among diabetic patients without prior CVD but with at least one CVD risk factor, 59.8% were not on anti-platelet therapy.
• Only 7.1% of those not on anti-platelet therapy had a documented contraindication, suggesting underutilization.

Conclusions:

• High utilization of anti-platelet therapy is feasible in diabetic patients with established CVD.
• Contraindications do not adequately explain the low use of anti-platelet therapy in diabetic patients without prior CVD but with risk factors.
• There may be opportunities to improve secondary prevention strategies through increased anti-platelet use in high-risk diabetic patients.